Ovarian Cancer Clinical Trials

Showing 201-220 of 1,169 trials

Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry

NCT02302742

PROGECT is a registry for patients with Triple Negative breast cancer (TNBC) or patients who have an identified germline mutations (such as a mutation on the BRCA1 or BRCA2 genes).

Breast CancerHereditary Breast and Ovarian Cancer

University of Kansas Medical Center1,500 participantsStarted Mar 2011

Hays, Kansas, United States • Kansas City, Kansas, United States • Overland Park, Kansas, United States +8 more locations

RECRUITINGPhase 2

WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC

NCT04644289

This is a multi-center, prospective, open-label, phase II trial. Patients with suspected advanced ovarian cancer planned to undergo diagnostic laparoscopy for histologic confirmation and evaluation of disease spread will be registered into the trial after providing a 1st written informed consent.

Epithelial Ovarian Cancer

AGO Research GmbH60 participantsStarted May 2022

Mannheim, Baden-Wurttemberg, Germany • München, Bavaria, Germany • Hamburg, Hamburg, Germany +3 more locations

Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry

WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC

Related Searches

Trial on Radical Upfront Surgery in Advanced Ovarian Cancer

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer

AOH1996 for the Treatment of Refractory Solid Tumors

HRD Tests for Ovarian cancER

Assessing the Time Demands of Cancer

Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer

Identifying Genetic Targets in Gynecological Tumors

Efficacy and Safety of Sacituzumab in Patients With OCCC After Immunotherapy Progression

PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer .

Clinical Validation of Sophia Genetics Assay

Genetically Modified T Cells Against Ovarian Cancer

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors

The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons

OCS Products Based on Exosome Technology Were Applied in the Recurrence Monitoring Study After the Initial Treatment of Baseline CA125-negative Ovarian Cancer